Immunotherapy. Oncology. Microbial Precision for Next-Generation Biologics.

At Mika Biologics, we partner with the most innovative biopharma and biotech companies to accelerate the therapies that will define the future: immunotherapies, oncology treatments, and breakthrough biologics that push beyond conventional limits.

We are not a generalist CDMO. We are a specialist microbial-first CDMO—experts in expression systems, phage-derived scaffolds, cytokines, nanoparticles, and engineered microbial platforms. For biopharma innovators, this means we provide not just manufacturing capacity, but true technical partnership, helping solve problems that large mammalian-focused CDMOs overlook.

Our mission is simple: to be the best microbial & phage CDMO in the U.S., the world, and the galaxy—the indispensable partner for biopharma and biotech innovators.

What Biopharma & Biotech Companies Value

Every biopharma/biotech partnership is built on a few critical needs. We’ve listened to the industry and designed Mika around them.

Speed to IND and Clinic

Biopharma companies operate under immense pressure to move programs quickly from discovery to Phase I trials. Every month saved is not just cost avoided but competitive advantage gained. Mika’s microbial-first systems—E. coli, yeast, fungi, cell-free—are inherently faster than mammalian cell lines, enabling rapid prototyping and faster path to IND.

Technical Depth in “Difficult” Molecules

Cytokines, CRISPR proteins, nanoparticles, VLPs—these are high-value but technically challenging biologics. Many CDMOs decline these projects. Mika specializes in them, with proprietary refolding, folding, and activity validation workflows that make the “impossible” possible.

Flexibility & Orphan-Scale Runs

Biotech pipelines often require small-batch GMP runs (10–200 L) to serve rare diseases or early-phase trials. Big CDMOs deprioritize such programs. Mika embraces them as our sweet spot.

Cost-Efficient, Scalable Platforms

Microbial systems not only move faster—they scale more predictably and with lower cost of goods (COGs). For biopharma, this means long-term sustainability.

Regulatory Readiness

Biopharma companies need CMC strategy, comparability studies, and IND/CTA packages that pass scrutiny. Mika is FDA-registered, EU-compliant, ISO-aligned—and our focus on microbial systems gives us regulatory fluency in areas many CDMOs overlook (e.g., endotoxin-free biologics).

Current Technical Needs in Biopharma & Biotech

The landscape is shifting. Innovators need partners who understand today’s challenges and tomorrow’s frontiers.

1. Cytokine Manufacturing
   • IL-2, IL-7, IL-15 are central to immunotherapy.
   • Solubility and folding remain technical hurdles.
   • Biopharma needs CDMOs with refolding expertise + functional validation assays.
2. Checkpoint Proteins & Fusions
   • PD-L1, CTLA-4 ligands, novel checkpoint-fusion proteins.
   • Require microbial expression + glycoengineering.
3. Cell Therapy Enablers
   • Cytokines for CAR-T/NK expansion.
   • Plasmids, enzymes, and CRISPR proteins for ex vivo modification.
4. Vaccine Scaffolds & VLPs
   • Biopharma is pushing beyond COVID—toward oncology vaccines and nanoparticle scaffolds.
   • Needs microbial platforms that assemble immunogenic VLPs reliably.
5. Nanoparticles & Next-Gen Biomaterials
   • Self-assembling protein nanoparticles as drug carriers.
   • Require specialized expertise in protein design and microbial assembly.
6. Engineered Probiotics (LBPs)
   • Microbiome therapies for autoimmune and oncology.
   • Need anaerobic fermentation, containment GMP, viability-preserving formulations.
7. Endotoxin-Free Biologics
   • Plasmids and cytokines must meet ultra-low endotoxin thresholds.
   • ClearColi® and engineered microbial strains are in demand.

Innovation in the Biopharma Industry Today

Mika exists at the cutting edge of industry innovation:

• Oncology Vaccines – microbial VLPs and scaffolds driving tumor immunology.
• CAR-T & NK Therapies – cytokines fueling cell expansion.
• CRISPR Therapeutics – nucleases and editors manufactured at GMP-grade.
• Engineered Microbes – probiotics reprogrammed as living therapeutics.
• Nanomedicine – biologic nanoparticles carrying drugs and antigens.
• Rare Disease Therapies – orphan cytokines and enzymes manufactured at small scale.
• Pandemic Preparedness – microbial vaccines and cell-free systems for rapid outbreak response.

Mika is positioned at the intersection of immune innovation, microbial mastery, and next-gen biologics.

How Mika Delivers Value to Biopharma & Biotech

Faster IND Submissions

Our microbial-first systems cut weeks to months off development. Cell-free systems enable rapid prototyping within days.

Lower Costs, Higher Yields

By eliminating mammalian cell dependencies, we reduce COGs while achieving gram-per-liter yields in microbial systems.

Regulatory Confidence

Our ISO-aligned, FDA/EU-ready systems provide clean CMC packages with strong QC and comparability data.

Specialized Niche Focus

We don’t dilute our attention with CHO. We live and breathe microbial systems—giving clients sharper expertise.

Global Scale Readiness

From orphan-scale GMP (10–200 L) to pandemic-scale supply (20,000 L with partners), Mika adapts to biopharma program needs.

Technical Capabilities That Matter to Biopharma

• Fermentation: E. coli, yeast, fungi (1–2000 L, with partner capacity up to 20,000 L).
• Downstream: TFF, chromatography, lyophilization, refolding suites.
• Analytics: HPLC/UHPLC, mass spec, ELISA, flow cytometry, immunoassays.
• Quality: GMP, IND/CTA documentation, regulatory support.
• Digital Backbone: PAT, electronic batch records, real-time QC integration.

Case Examples

• Immunotherapy Biotech – partnered with Mika to produce GMP IL-15 for CAR-T expansion, accelerating IND filing.
• Oncology Startup – VLP-based cancer vaccine scaffold manufactured at 500 L, validated in preclinical models.
• CRISPR Innovator – Cas12 protein scaled from bench to GMP, enabling diagnostic kit launch.
• Rare Disease Foundation – lysosomal enzyme manufactured at 50 L GMP for Phase I trial.

Top 10 Technical FAQs for Biopharma Clients

1. What microbial systems does Mika specialize in?
E. coli (including endotoxin-free ClearColi®), yeast (Pichia, Saccharomyces), fungi (Aspergillus, Trichoderma), and engineered probiotics.

2. Can Mika handle cytokine folding challenges?
Yes. We have proprietary refolding workflows, chaperone co-expression systems, and activity validation assays for ILs, interferons, and GFs.

3. How does Mika ensure regulatory readiness?
ISO-aligned, FDA-registered, EU-compliant facilities. IND/CTA support, comparability studies, and QC assays integrated from early stage.

4. What scale can Mika support?
1 L → 2000 L in-house, up to 20,000 L with partners. We specialize in orphan-scale GMP runs (10–200 L).

5. Does Mika offer plasmid production?
Yes—endotoxin-free plasmids via ClearColi® strains, GMP-grade, validated for gene therapy and mRNA platforms.

6. Can Mika support engineered probiotics?
Yes—anaerobic fermentation, GMP containment, cryopreservation, capsule/lyophilized formulations.

7. What about VLPs and nanoparticle scaffolds?
We produce microbial VLPs, phage-derived scaffolds, and engineered nanoparticles with full EM/DLS characterization.

8. How does Mika handle QC for immune biologics?
Activity-based assays (receptor binding, cell-based functional validation), plus full analytics suite (HPLC, ELISA, MS).

9. Do you support pandemic-scale vaccine production?
Yes—our microbial-first systems allow rapid antigen pivoting and large-scale fermentation.

10. Why choose Mika over a mammalian CDMO?
Speed, cost, scalability, and niche expertise. We don’t dilute focus—we are the microbial & phage experts.

Closing Statement

Biopharma and biotech companies are driving the most important innovations of our time: immunotherapies, oncology treatments, rare disease cures, pandemic vaccines. To deliver these breakthroughs, they need partners who can move fast, master difficult molecules, and scale globally.

That is Mika Biologics. We are the best microbial & phage CDMO in the U.S., the world, and the galaxy—with unmatched expertise in cytokines, VLPs, nanoparticles, engineered probiotics, and endotoxin-free biologics.

We don’t just manufacture for biopharma. We enable biopharma innovation.

Mika Biologics. Microbial Systems. Immune Innovation. Beyond the Cell.